Sotorasib, a KRAS G12C inhibitor, achieved disease control rates of 88.1% in the treatment of NSCLC and 84% in the treatment of pancreatic cancer [3, 4]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.